Status:
TERMINATED
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Oncology Specialists, S.C.
Collaborating Sponsors:
Sanofi-Synthelabo
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects. Oxaliplatin and doc...
Detailed Description
This study is a Phase II study designed to evaluate the toxicity profile for oxaliplatin and docetaxel and to determine the response rate to this study drug combination. The primary objective of the s...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)
- Patients must have measurable disease
- Age greater than or equal to 18 years
- ECOG performance score of 0, 1, or 2
- Absolute neutrophil count (ANC) \> 1,500
- Platelets \> 100,000
- Serum creatinine \< 1.5mg/dL
- Serum total bilirubin \< 1.5mg/dL
- Alkaline phosphatase \< 3 times the upper limit of normal
- SGOT/SGPT \< 3 times the upper limit of normal
- Patients must be recovered from the effects of any prior surgery or RT.
- Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.
- Patients of childbearing potential and their partners must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medications.
Exclusion
- Patients with an active infection \> 38.5 degrees Celsius within 3 days of the first scheduled day of protocol treatment
- Patients with active central nervous system (CNS) metastasis. Patients with stable CNS disease, who have undergone radiotherapy at least 4 weeks prior to the planned first protocol treatment and who have been on a stable dose of corticosteroids for 2 weeks are eligible for the trial.
- History of prior malignancy within the past 5 years except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasm, or localized prostate cancer with a current prostate specific antigen (PSA) of \< 1.0 mg/dL
- Patients with known hypersensitivity to any of the components of oxaliplatin or docetaxel
- Patients who have had prior chemotherapy for lung cancer
- Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment
- Grade 2 peripheral neuropathy
- Patients who are pregnant or lactating
- Any other medical condition, including mental illness or substance abuse deemed by the investigator to be likely to interfere with the patients' ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
- History of allogeneic transplant
- Known HIV, hepatitis B or C (active, previously treated, or both)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00145418
Start Date
February 1 2005
End Date
March 1 2010
Last Update
June 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Specialists, SC
Park Ridge, Illinois, United States, 60068